SCLX Q3 2024 Earnings — Scilex Holding Company Revenue & Financial Results | Market Cap Arena

SCLXScilex Holding Company

$73M

Q3 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$14M+42.7% YoY

Gross Profit

$11M73.9% margin

Operating Income

-$20M-138.0% margin

Net Income

-$4M-30.4% margin

EPS (Diluted)

$-1.21

QoQ Revenue Growth

-11.8%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$100M

Total Liabilities

$312M

Stockholders' Equity

-$211M

Cash & Equivalents

$77,000

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$10M	+42.7%
Gross Profit	$11M	$7M	+58.6%
Operating Income	-$20M	-$39M	+48.7%
Net Income	-$4M	-$36M	+87.6%